Sari PesonenCo-founder and CSO at Valo TherapeuticsSpeaker
Agenda Sessions
PeptiCRAd platform as a novel intratumoral fusion immunotherapy targeting heterogeneous antigen profile of solid tumors
, 10:20View Session